Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Extension Study of the Long-term Safety, Tolerability and Efficacy of Ambrisentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

NCT01894022 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01894022
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01894022 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Extension Study of the Long-term Safety, Tolerability and Efficacy of Ambrisentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Terminated
Start date
January 23, 2014
Completion date
November 18, 2015
Enrollment
19 (actual)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension